26 completed, 5 unknown, 3 terminated, 2 active not recruiting. 41 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 41 | Completed 26, Unknown 5, Terminated 3, Active not recruiting 2, Not yet recruiting 2, Withdrawn 2, Recruiting 1 |
Follow ADHD: new trials by email Literature Review of ADHD trials Research Report on ADHD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder Delayed-release, extended-release methylphenidate, Placebo - ADHD, Cannabis Use Disorder | Phase 4 | Not yet recruiting | Massachusetts General Hospital | 66 | 2026-11-01 | 2026-09-28 |
| EEG Biomarkers for ADHD Stimulant Treatment methylphenidate HCl, Mixed amphetamine salts extended release - ADHD | Phase 4 | Not yet recruiting | Boston Children's Hospital | 220 | 2026-09-15 | 2026-06-16 |
| Multimodal Brain Imaging of Methylphenidate in Children and Adolescents With ADHD Methylphenidate, Placebo - ADHD | Phase 4 | Withdrawn | Johns Hopkins University | 2024-04-16 | 2024-03-15 | |
| AWARE: Management of ADHD in Autism Spectrum Disorder Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant. - ADHD, Autism Spectrum Disorder | Phase 4 | Recruiting | Daniel Coury | 500 | 2023-10-01 | 2026-10-22 |
| Single and Combined Effects of Behavioral, Academic, and Medication Treatments for ADHD in the Classroom Methylphenidate Hydrochloride ER, Behavioral classroom, Placebo - ADHD | Phase 4 | Active not recruiting | Florida International University | 288 | 2022-06-13 | 2025-08-27 |
| The Effects of a Single Dose of Methylphenidate on Motor Performance MPH - ADHD | Phase 4 | Unknown | Loewenstein Hospital | 200 | 2021-05-27 | 2023-12-20 |
| Adjuvant Effects of Vitamin A and Vitamin D Supplementation on Treatment of Children With ADHD Placebos, vitamin AD, vitamin D - ADHD | Phase 4 | Unknown | Chen Li | 504 | 2021-02-25 | 2021-04-06 |
| Evaluating Treatment of ADHD in Children With Down Syndrome Quillivant XR, Placebo - Down Syndrome, ADHD | Phase 4 | Active not recruiting | Children's Hospital Medical Center, Cincinnati | 100 | 2020-10-02 | 2026-08-10 |
| Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk Methylphenidate, Atomoxetine - ADHD, Attention Deficit Hyperactivity Disorder | Phase 4 | Unknown | Icahn School of Medicine at Mount Sinai | 44 | 2019-06-04 | 2024-08-09 |
| Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention CNS Stimulant - ADHD | Phase 4 | Terminated | Milton S. Hershey Medical Center | 11 | 2018-06-01 | 2025-08-26 |
| Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD Methylphenidate - ADHD, Attention Deficit Hyperactivity Disorder | Phase 4 | Unknown | Icahn School of Medicine at Mount Sinai | 500 | 2018-03-04 | 2024-08-09 |
| Irritability in Children With ADHD and Emotion Dysregulation Methylphenidate, aripiprazole, and combination - Irritable Mood, ADHD | Phase 4 | Completed | Tri-Service General Hospital (TSGH) | 36 | 2017-04-21 | 2023-08-07 |
| Network Connectivity and Inhibitory Control Under Atomoxetin Challenge- A Pharmacological 'Resting State' and 'Inhibiton Task' Study in Patients With ADHD Atomoxetine, Placebos - ADHD | Phase 4 | Completed | RWTH Aachen University | 38 | 2016-05-01 | 2018-09-07 |
| Predicting Treatment Response to Stimulants in Adult ADHD Using Functional Magnetic Resonance Imaging OROS-MPH - ADHD | Phase 4 | Withdrawn | Massachusetts General Hospital | 2015-04-01 | 2015-04-28 | |
| The Effects of ADHD Medication (TEAM) Study OROS-Methylphenidate (MPH) - ADHD | Phase 4 | Completed | Children's Hospital Medical Center, Cincinnati | 204 | 2015-01-12 | 2023-12-21 |
| Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study Very Low Dose Quillivant XR, Low Dose Quillivant XR, Moderate Dose Quillivant XR - ADHD, Autism | Phase 4 | Completed | Seattle Children's Hospital | 36 | 2014-09-01 | 2017-08-01 |
| A Study of Combination Therapy in Children With ADHD Methylphenidate ER, Cyproheptadine - ADHD, Attention Deficit Hyperactivity Disorder | Phase 4 | Completed | Douglas Sears | 99 | 2014-03-01 | 2015-04-10 |
| Methylphenidate for Attention Problems After Pediatric TBI Methylphenidate, Placebo - Traumatic Brain Injury, TBI | Phase 4 | Completed | Children's Hospital Medical Center, Cincinnati | 26 | 2013-11-01 | 2020-06-04 |
| Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation Lisdexamfetamine - ADHD | Phase 4 | Completed | Jeffrey Newcorn | 30 | 2013-03-01 | 2018-06-06 |
| A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder Naltrexone, Placebo - ADHD, Attention Deficit Hyperactivity Disorder | Phase 4 | Terminated | Massachusetts General Hospital | 3 | 2012-11-01 | 2016-05-27 |
Showing 20 of 41. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (41) · Autistic Disorder (2) · Spasm (2) · Substance-Related Disorders (2) · Attention Deficit and Disruptive Behavior Disorders (1) · Autism Spectrum Disorder (1) · Bipolar Disorder (1) · Brain Injuries, Traumatic (1) · Cigarette Smoking (1) · Down Syndrome (1) · Marijuana Abuse (1) · Motor Activity (1) · Neurodevelopmental Disorders (1) · Trichotillomania (1)
Mental Disorders (41) · Attention Deficit and Disruptive Behavior Disorders (40) · Neurodevelopmental Disorders (40) · Nervous System Diseases (4) · Neurologic Manifestations (3) · Behavior (2) · Chemically-Induced Disorders (2) · Child Development Disorders, Pervasive (2) · Neuromuscular Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Abnormalities, Multiple (1) · Anxiety Disorders (1) · Autism Spectrum Disorder (1) · Bipolar and Related Disorders (1)
Methylphenidate (25) · Atomoxetine Hydrochloride (8) · 5,10-dihydro-5-methylphenazine (5) · Lisdexamfetamine Dimesylate (2) · Naltrexone (2) · Adenosine Monophosphate (1) · Aripiprazole (1) · Central Nervous System Stimulants (1) · Cyproheptadine (1) · Galantamine (1) · Memantine (1) · SLI381 (1) · Vitamin D (1)
Massachusetts General Hospital (13) · Children's Hospital Medical Center, Cincinnati (4) · Icahn School of Medicine at Mount Sinai (4) · Eli Lilly and Company (2) · Florida International University (2) · Boston Children's Hospital (1) · Chen Li (1) · Daniel Coury (1) · Douglas Sears (1) · Geha Mental Health Center (1) · Jeffrey Newcorn (1) · Johns Hopkins University (1) · Loewenstein Hospital (1) · Milton S. Hershey Medical Center (1) · Prof. Huss (1)
United States (34) · Canada (2) · Germany (2) · Israel (2) · China (1) · Netherlands (1) · Taiwan (1)
Jeffrey Newcorn, MD (5) · Joseph Biederman, MD (5) · Mark Stein, PhD (2) · Paul Hammerness, MD (2) · Tanya Froehlich, MD (2) · Thomas J Spencer, MD (2) · Timothy Wilens, MD (2) · Anna Esbensen, PhD (1) · Benjamin Handen, MD (1) · Brad Kurowski, MS, MD (1) · Chin-Bin Yeh, MD., PhD. (1) · Daniel Coury, MD (1) · Edmund Volkerts, PhD (1)
PMID 25019647, PMID 14595084, PMID 15827573, PMID 16371674, PMID 19142107, PMID 19394037, PMID 20492851, PMID 20645078, PMID 21143432, PMID 21303732, PMID 21586916, PMID 22029549, PMID 23639146, PMID 24796970, PMID 25575616, PMID 25659477, PMID 27462065, PMID 27991835, PMID 28640990, PMID 29617066, PMID 29661516, PMID 30169436, PMID 34135055, PMID 38101205, PMID 38824626, PMID 40238929, PMID 41567292, PMID 42620964
K12DA000357 (1), R01HD093612 (1), R01MH083665 (1), R01MH095766 (1), R21DA045218 (1)